How Many Cancers Are Linked with HPV Each Year?
Each year, about 32,000 new cases of cancer are found in parts of the body where human papillomavirus (HPV) is often found. HPV causes about 26,200 of these cancers.
Number of HPV-Associated Cancer Cases per Year
An HPV-associated cancer is a cancer that is diagnosed in a part of the body where HPV is often found. These parts of the body include the cervix, anus, penis, vagina, vulva, and oropharynx (back of the throat, including the base of the tongue and tonsils). Researchers use cancer registry data to estimate the number of HPV-associated cancers in the United States by looking at cancer in parts of the body and cancer cell types that are more likely to be caused by HPV. Cancer registries do not routinely collect data on whether HPV is in the cancer tissue. CDC studies1 2 have reported the number of HPV-associated cancer cases per year, and these studies have more information on how HPV-associated numbers were calculated.
Number of HPV-Attributable Cancer Cases per Year
An HPV-attributable cancer is a cancer that is probably caused by HPV. HPV causes nearly all cervical cancers and many cancers of the anus, penis, vagina, vulva, and oropharynx. CDC studies3 4 5 used population-based data from cancer tissue to estimate the percentage of these cancers that are probably caused by HPV.
To find the number of HPV-attributable cancers, multiply the number of HPV-associated cancers by the percentage of these cancers that are probably caused by HPV. For example, about 11,279 women are diagnosed with cervical cancer each year, and about 91% of cervical cancers are caused by HPV. 91% of 11,279 is 10,264, or about 10,300, as shown in the table below.
|Cancer site||Average number of cancers per year in sites where HPV is often found (HPV-associated cancers)||Percentage probably caused by HPV||Number probably caused by HPV|
|Male||Female||Both Sexes||Male||Female||Both Sexes|
1Centers for Disease Control and Prevention (CDC). Human papillomavirus–associated cancers—United States, 2004–2008. MMWR 2012;61(15):258–261.
2Supplement: Assessing the Burden of HPV-Associated Cancers in the United States. Cancer 2008;113(S10):2837–3057.
3Steinau M, Unger ER, Hernandez BY, Goodman MT, Copeland G, Hopenhayn C, Cozen W, Saber MS, Huang Y, Peters ES, Lynch CF, Wilkinson EJ, Rajeevan MS, Lyu C, Saraiya M. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. Journal of Lower Genital Tract Disease 2013. In press.
4Gargano JW, Wilkinson EJ, Unger ER, Steinau M, Watson M, Huang Y, Copeland G, Cozen W, Goodman MT, Hopenhayn C, Lynch CF, Hernandez BY, Peters ES, Saber MS, Lyu CW, Sands LA, Saraiya M. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. Journal of Lower Genital Tract Disease 2012;16(4):471–479.
5Presentation at the 28th International Papillomavirus conference, 2012. Puerto Rico. EPO9-728 Population-based HPV genotype distribution in 8 cancers in the United States: potential current and future (9-valent) vaccine protection. Presenter: Mona Saraiya (United States).
- Centers for Disease Control and Prevention
Division of Cancer Prevention and Control
c/o CDC Warehouse
3719 N Peachtree Rd
Building 100 MS F-76
Chamblee GA 30341
TTY: (888) 232-6348
- Contact CDC-INFO